trending Market Intelligence /marketintelligence/en/news-insights/trending/AnrFYlDPqZMeIeO-G8XZyA2 content esgSubNav
In This List

Affimed's drug combination for Hodgkin lymphoma well-tolerated in phase 1b study

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Affimed's drug combination for Hodgkin lymphoma well-tolerated in phase 1b study

Affimed NV said a combination of its AFM13 drug and Merck & Co. Inc.'s Keytruda was well-tolerated in patients with relapsed or refractory Hodgkin lymphoma in an ongoing phase 1b study.

The combination treatment is being investigated as a salvage therapy for patients who have failed prior standard treatments like brentuximab vedotin.

The early results showed a three-month overall response rate of 83%, compared to the historical overall response rate of Keytruda as a monotherapy of 58% to 63%.

Affimed said the most common side effects observed were infusion-related reactions, nausea, diarrhea, headache, pyrexia and rash.

The preliminary data was presented by Affimed at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta.